Clinical Studies


A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy


A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants with Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-Pegylated Interferon-β or No Disease Modifying Therapy.  


H8H-MC-LAHV(a) Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of SPN-538 as a Therapy for the Prevention of Migraine in Subjects Ages 6-11 Years

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine

Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine

Parkinson’s Disease:

Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight into Parkinson’s Disease Status (APPRISE)


Brain-Derived Neurotrophic Factor Precision Medicine for Parkinson’s Disease – Levodopa Study (BDNF-LD)


A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson’s Disease (TEMPO-1 TRIAL)


A Multicenter, Randomized, Active-Controlled, Double-Blind, Double Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations (BouNDless

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson’s disease

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and

Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components BK-JM-201

58-Week Open-Label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)  

Trial of Parkinson’s and Zoledronic Acid (TOPAZ)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

An Open-Label Study of the Long-Term Safety and Tolerability of SAGE-324 in Participants with Essential Tremor

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease

Alzheimer’s Disease:

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Myasthenia Gravis 

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis


Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy


A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the secondary prevention of ischemic stroke in adult patients with an acute non-cardioembolic ischemic stroke or high-risk TIA (OCEANIC-Stroke)

A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, after an Ischemic Stroke or High Risk Transient Ischemic Attack

Thyroid Eye Disease:

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Investigator Initiated:  

Characteristics of Ocular Myasthenia Gravis


Optical Coherence Tomography and Cervical Dystonia: Is there a link between the retina and an isolated focal dystonia that is disease specific?  


Short and Long Term Outcomes of an Outpatient Physical Therapy Protocol for the Treatment of Functional Movement Disorders


Localization of vergence centers using functional MRI


Does Light Exposure Impact Seizure Frequency? Testing a Hypothesis


Feasibility of a text messaging intervention to enhance self-management behaviors in patients with migraine.


International Research:


MISC-CBO: A cluster randomized control trial to improve the mental health of OVC in South Africa.

Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae. 


Culture-specific neurodevelopmental assessment of HIV-affected children.

Culture-specific neurodevelopmental assessment of HIV-affected children: Home-Based Evaluation through Cloud-Readiness Enhancement. 

Impact of household air pollution (HAP) in-utero through early childhood on neurocognitive. development from infancy to 8 years (HAPCOG Study). 

Understanding maternal-fetal zika virus transmission and its complications in Nicaragua.


If interested in study participation, please contact:

Aubrey Alexander, CCRC

Clinical Research Manager

Department of Neurology

Phone:  517-884-8920



Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824